〔Abstract〕 Objective To analyze the efficacy, safety, and social function of palmitic acid palipidone injection in the treatment of community schizophrenia patients. Methods A total of 80 patients with schizophrenia admitted to Zhongshan Third People's Hospital from March 2021 to June 2022, who lived in the community and were included in the management, were selected for treatment with palmitic acid paliperidone injection. At the time of enrollment, the 8 weeks after enrollment, 6 months after enrollment, and 1 year after enrollment, the brief psychiatric rating scale (BPRS), the modified overt aggression scale (MOAS), and the personal and social performance scale (PSP), the clinical global impressions-severity (CGI-S), the treatment emergent symptom scale (TESS) were evaluated. Results Compared to the time of enrollment, the BPRS and MOAS scores of patients at 8 weeks, 6 months, and 1 year after enrollment were decreased, with statistically significant difference (P < 0.05). Compared to the time of enrollment, the PSP score of patients were increased at 8 weeks, 6 months, and 1 year after enrollment, while the CGI-S score were decreased, with statistically significant difference (P < 0.05). The TESS scores of patients at 0.5 and 1 year after enrollment were lower than those at the time of enrollment, and the TESS scores at 1 year after enrollment were lower than those at 8 weeks after enrollment, with statistically significant difference (P < 0.05). Conclusion The application of palmitic acid paliperidone injection in the treatment of community schizophrenia patients has a definite therapeutic effect, which can alleviate symptoms, aggressive behavior, disease severity, and has high safety. It can also improve pationts' social function.